Post-earnings recap
Reported
Tue, Apr 30, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that 10X Genomics Inc faced challenges with its EPS, missing expectations. However, the stock rose by 3.10%, likely driven by investor optimism about the company's long-term growth strategy and commitment to innovation despite the current losses.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | -9.17% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious optimism about future growth. They emphasized their focus on long-term strategies and innovation.
We are focused on our long-term growth strategy despite current challenges.
Our commitment to innovation remains strong as we navigate this period.